# **Product Datasheet**

# Serpin A3/alpha 1-Antichymotrypsin Antibody (AACT/1451) [DyLight 755] NBP2-54339IR

Unit Size: 100 ul

Store at 4C in the dark.

www.novusbio.com



technical@novusbio.com

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NBP2-54339IR

Updated 10/26/2023 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications
Submit a review at www.novusbio.com/reviews/destination/NBP2-54339IR



## **NBP2-54339IR**

Serpin A3/alpha 1-Antichymotrypsin Antibody (AACT/1451) [DyLight 755]

Serpin A3/alpha 1-Antichymotrypsin Antibody (AAC1/1451) [DyLight 755]	
Product Information	
Unit Size	100 ul
Concentration	Please see the vial label for concentration. If unlisted please contact technical services.
Storage	Store at 4C in the dark.
Clonality	Monoclonal
Clone	AACT/1451
Preservative	0.05% Sodium Azide
Isotype	IgG1
Conjugate	DyLight 755
Purity	Protein A or G purified
Buffer	50mM Sodium Borate
Product Description	
Description	This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
Host	Mouse
Gene ID	12
Gene Symbol	SERPINA3
Species	Human
Marker	Histiocytoma Marker
Specificity/Sensitivity	It recognizes a protein of 65-76kDa, which is identified antichymotrypsin (AACT). AACT is a plasma protease inhibitor synthesized in the liver as a single glycopeptide chain. In human, the normal serum level of AACT is about onetenth that of their concentrations in plasma increase in response to trauma, surgery and infection. Elevated levels of AACT are widely, but not universally, reported in the cerebrospinal fluid and plasma of AD patients. Prostate-specific antigen (PSA) and its SDS-stable complex with AACT are in widespread use as markers for the diagnosis of prostate cancer. AACT deficiency may also be a possible cause of chronic liver disease. AACT antibody reacts with histiocytes and histiocytic neoplasms. It is widely used to identify histiocytes and tumors derived from them. Acinar tumors of the pancreas and salivary gland may also exhibit AACT positivity.
Immunogen	Recombinant human Serpin A3/alpha 1-Antichymotrypsin protein fragment (around aa 49-187) (exact sequence is proprietary) (Uniprot: P01011)
Notes	DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
Product Application Details	
Applications	Immunohistochemistry, Immunohistochemistry-Paraffin, CyTOF-ready
Recommended Dilutions	Immunohistochemistry, Immunohistochemistry-Paraffin, CyTOF-ready
Application Notes	Optimal dilution of this antibody should be experimentally determined.





# Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112

USA

Phone: 303.730.1950 Toll Free: 1.888.506.6887

Fax: 303.730.1966 novus@novusbio.com

#### **Bio-Techne Ltd**

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom

Phone: (44) (0) 1235 529449 Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

#### **Bio-Techne Canada**

21 Canmotor Ave Toronto, ON M8Z 4E6

Canada

Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402

canada.inquires@bio-techne.com

#### **General Contact Information**

www.novusbio.com

Technical Support: technical@novusbio.com

Orders: orders@novusbio.com General: novus@novusbio.com

## **Products Related to NBP2-54339IR**

NBP1-97005IR Mouse IgG1 Isotype Control (MG1) [DyLight 755]

NBP1-90295PEP Serpin A3/alpha 1-Antichymotrypsin Recombinant Protein Antigen

210-TA-005 TNF-alpha [Unconjugated]

1295-PI-010 Serpin A3/alpha 1-Antichymotrypsin

#### Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-54339IR

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications

